Xiao Gen-Fa, Xu Shang-Hua, Chao Yi, Xie Liang-Di, Xu Chang-Sheng, Wang Hua-Jun
Department of Cardiology, The Second Hospital of Nanping, Jianyang, Fujian 354200, China.
Department of Cardiology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian 353000, China.
Eur J Pharmacol. 2014 Mar 15;727:29-34. doi: 10.1016/j.ejphar.2014.01.051. Epub 2014 Jan 31.
Increased expression of the p22(phox) subunit of the NADPH oxidase complex may possibly contribute to both the enzyme׳s increased activation and the occurrence of oxidative stress during hyperhomocysteinaemia. However, the activation of peroxisome proliferator-activated receptor (PPAR) δ has been shown to inhibit p22(phox) expression. The purpose of this study was to elucidate the signaling pathway by which PPARδ activation regulated homocysteine-induced expression of p22(phox). EA.hy926 cells were stimulated with homocysteine (Hcy) in the presence or absence of the PPARδ-specific agonist, GW0742, or of various signaling inhibitors, including the antioxidants N-acetylcysteine (NAC), NADPH oxidase inhibitor, diphenyleneiodonium (DPI), and the p38MAPK inhibitor, SB203580. Expression of p22(phox) mRNA and phospho-p38MAPK protein were measured by real-time PCR and western blot analysis, respectively, and reactive oxygen species were measured by fluorescence microscopy. Our data indicate that Hcy increased both the expression of p22(phox) in a concentration-dependent manner and also increased phosphoryation of p38 MAPK and reactive oxygen species production in a time-dependent manner. However, activation of the PPARδ signaling pathway by the agonist GW0742 reversed all these changes induced by Hcy. Furthermore, SB203580 prevented the increase in p22(phox) expression, and NAC and DPI not only inhibited Hcy-induced phosphorylation of p38MAPK, but also prevented expression of p22(phox). These findings indicate that Hcy-induced expression of p22(phox) is regulated by the reactive oxygen species/p38MAPK pathway and that PPARδ activation is capable of attenuating this pathway by eliminating Hcy-induced reactive oxygen species production.
NADPH氧化酶复合物的p22(phox)亚基表达增加可能有助于该酶在高同型半胱氨酸血症期间的激活增加以及氧化应激的发生。然而,过氧化物酶体增殖物激活受体(PPAR)δ的激活已被证明可抑制p22(phox)的表达。本研究的目的是阐明PPARδ激活调节同型半胱氨酸诱导的p22(phox)表达的信号通路。在存在或不存在PPARδ特异性激动剂GW0742或各种信号抑制剂的情况下,用同型半胱氨酸(Hcy)刺激EA.hy926细胞,这些信号抑制剂包括抗氧化剂N-乙酰半胱氨酸(NAC)、NADPH氧化酶抑制剂二苯基碘鎓(DPI)和p38丝裂原活化蛋白激酶(p38MAPK)抑制剂SB203580。分别通过实时PCR和蛋白质印迹分析测量p22(phox) mRNA的表达和磷酸化p38MAPK蛋白,通过荧光显微镜测量活性氧。我们的数据表明,Hcy以浓度依赖性方式增加p22(phox)的表达,并且还以时间依赖性方式增加p38 MAPK的磷酸化和活性氧的产生。然而,激动剂GW0742激活PPARδ信号通路逆转了Hcy诱导的所有这些变化。此外,SB203580阻止了p22(phox)表达的增加,NAC和DPI不仅抑制了Hcy诱导的p38MAPK磷酸化,还阻止了p22(phox)的表达。这些发现表明,Hcy诱导的p22(phox)表达受活性氧/p38MAPK通路调节,并且PPARδ激活能够通过消除Hcy诱导的活性氧产生来减弱该通路。